Ser225
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser225  -  Ets-2 (human)

Site Information
LDsMCPAstPsVLSS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 30320501

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 1 ) , MCF-7 (breast cell) ( 2 )

Upstream Regulation
Kinases, in vitro:
CDK10 (human) ( 2 )

Downstream Regulation
Effects of modification on Ets-2:
protein degradation ( 1 , 2 )

References 

1

Carrero ZI, et al. (2016) Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation. Oncotarget 7, 12554-67
26871468   Curated Info

2

Guen VJ, et al. (2013) CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc Natl Acad Sci U S A 110, 19525-30
24218572   Curated Info